Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Albireo Pharma Inc (ALBO)

26.03   -0.14 (-0.53%) 01-25 23:31
Open: 25.55 Pre. Close: 26.17
High: 26.5 Low: 24.98
Volume: 136,366 Market Cap: 502M
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 26.534 - 26.663 26.663 - 26.79
Low: 24.613 - 24.769 24.769 - 24.923
Close: 25.73 - 25.987 25.987 - 26.24

Technical analysis

as of: 2022-01-25 4:22:03 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 32.32     One year: 37.75
Support: Support1: 24.00    Support2: 21.73
Resistance: Resistance1: 27.67    Resistance2: 32.32
Pivot: 25.91
Moving Average: MA(5): 26.07     MA(20): 25.36
MA(100): 27.20     MA(250): 30.89
MACD: MACD(12,26): 0.54     Signal(9): 0.51
Stochastic oscillator: %K(14,3): 58.79     %D(3): 60.75
RSI: RSI(14): 54.83
52-week: High: 43.41  Low: 20.30  Change(%): -29.0
Average Vol(K): 3-Month: 190  10-Days: 180

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
ALBO has closed below upper band by 46.3%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 12 Jan 2022
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year? - Nasdaq

Thu, 06 Jan 2022
Albireo Pharma Stock (ALBO): Why The Price Increased - Pulse 2.0

Mon, 27 Dec 2021
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022 - Benzinga - Benzinga

Wed, 24 Nov 2021
Albireo: Reasons For A Successful Transformation Into A Commercial Company - Seeking Alpha

Wed, 10 Nov 2021
Albireo to Present at Upcoming Investor Conferences - GlobeNewswire

Thu, 04 Nov 2021
Albireo Pharma, inc (ALBO) Q3 2021 Earnings Call Transcript - Motley Fool

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Outperform Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 19
Shares Float (M) 17
% Held by Insiders 0.45
% Held by Institutions 85.41
Shares Short (K) 1,170
Shares Short P. Month (K) 1,130

Stock Financials

EPS -2.500
EPS Est This Year -3.640
EPS Est Next Year -3.440
Book Value (p.s.) 9.430
Profit Margin
Operating Margin -1122.74
Return on Assets (ttm) -24.9
Return on Equity (ttm) -24.3
Qtrly Rev. Growth 71.9
Gross Profit (p.s.) 0.431
Sales Per Share 0.559
EBITDA (p.s.) -6.261
Qtrly Earnings Growth
Operating Cash Flow (M) -122
Levered Free Cash Flow (M) -55

Stock Valuations

PE Ratio -10.41
PEG Ratio
Price to Book value 2.76
Price to Sales 46.60
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date 2016-11-03
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.